Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer
Sponsor: Peking Union Medical College Hospital
Summary
The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in resected pancreatic cancer. The main questions it aims to answer are: * prognostic value of baseline MRD; * the role of MRD dynamic changes after treatment in guiding treatment. Peripheral blood derived from participants will be obtained for MRD test before adjuvant chemotherapy initiation and at the first imaging assessment after chemotherapy.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2023-02-01
Completion Date
2030-02-01
Last Updated
2023-04-12
Healthy Volunteers
No
Conditions
Interventions
Later-line therapy
Another chemotherapy regimen, targeted therapy, or immunotherapy
Locations (1)
Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China